UA138375U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, C-terminal propeptide type I collagen (SISR), oxyproline, C-reactive protein (SRP). With a homozygous carrier of 786-CC, endothelin levels> 10 ng / ml, SISR <102 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, cartilage biopsy TSA.N.

Okorokov Diagnosis of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (emo5 1786C), the content of endothelin, C-terminal propeptide of type I collagen (SICP), oxyproline, and C-reactive protein (CRP) are determined in the patient's blood serum. and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, the emo5 7786C gene polymorphism is determined, the endothelin content is determined by the enzyme immunoassay method,

SISR, oxyproline, SRP. With homozygous carrier 786-SS and endothelin levels of 210 ng/ml,

SISR "102 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient 0., 68 years old, was hospitalized in the clinic due to pain syndrome of the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The eMmo5 gene polymorphism T786C was determined in blood serum, and the content of endothelin, SISR, oxyproline, SRP was determined by the immunoenzymatic method. A homozygous carrier of 786-SS was established, endothelin levels - 22 ng/ml, SICP - 78 ng/ml, oxyproline - 36 μmol/l, SRP - 18 mg/l. The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Zo

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (eMO5 T786C), the content of endothelin, C-terminal propeptide of type I collagen (SISR) is additionally determined in the patient's blood serum. of oxyproline, C-reactive protein (CRP) and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l predict the development of osteoarthritis. 00 Computer keyboardG. Payalnikovo (00000000 Ministry of Economic Development, Trade and Agriculture of Ukraine, St. M. Hrushevskyi, 12/2, Kyiv, 01008, Ukraine SE "Ukrainian Institute of Intellectual Property", str. Glazunova, 1, Kyiv - 42, 01601